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Background
According to EU legislation, genetically modified plants
(GM plants) should follow a scientific assessment of any
risk that they may pose to human and animal health,
including an allergenicity assessment. According to the
EFSA guidance1, the allergenicity assessment of GM plants
is structured into the assessment of i) the newly expressed
proteins and ii) the whole GM plant. For the latter and as
a part of the assessment, if the GM plant receiving the
introduced gene(s) is known to be allergenic, its endogen-
ous allergenicity is compared with that of its non-GM
comparator(s).
Methods
Historically, the assessment of endogenous allergenicity
has been performed by analytical methodologies based
on the use of human sera. Currently, new analytical
methods and profiling techniques (e.g. mass spectrometry
approaches) not based on human sera are now evolved
and could be used for these purposes. In view of these
new developments, EFSA recommended the possible
inclusion of key allergens in the comparative composi-
tional analysis to limit the use of human sera [1,2].
Results
There are several limitations associated with the use of
human sera, e.g. availability, reproducibility, variability
from allergic individuals, difficulty of obtaining well-
characterised allergic individuals and sera, etc. New
technologies, which do not require human sera for the
identification and quantification of allergens, have
shown to be very useful for risk assessment [3-5]. They
may provide important and reliable information on the
potential for unintended effects on the endogenous
allergenicity (i.e. over expression of allergens) due to the
genetic modification.
Conclusion
In order to avoid the use of human sera, alternative meth-
ods based on recent technological advances need to be
considered. For the allergenicity assessment of GM plants,
the inclusion of key allergens in the comparative composi-
tional analysis, as an additional parameter to be measured
by these new methods, could provide robust and reliable
information for risk assessment. In this context, when a
GM plant is compared with its non-GM comparator(s), an
important aspect to be considered is the natural variability
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